SCHEMBL1980479

SCHEMBL1980479

Cc1cc(F)ccc1Oc1ccc(N2C(=O)NC(C)(C)C2=O)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OXTR P30559 3/20 0.46
AR P10275 10/20 0.43
MMP13 P45452 2/20 0.41
NPBWR1 P48145 1/20 0.41
MCHR1 Q99705 1/20 0.41
SLC6A4 P31645 1/20 0.40
HSPB1 P04792 1/20 0.39
AVPR1A P37288 2/20 0.38
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
PGR P06401 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
ALOX12 P18054 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939511 1.00 OXTR (0.46) OXTRARMMP13NPBWR1MCHR1
SCHEMBL12595092 0.87 AR (0.43) OXTRARMMP13MEN1LMNA
SCHEMBL13720513 0.84 AR (0.44) OXTRARAVPR1ASMN1; SMN2
SCHEMBL30939575 0.80 AR (0.47) ARMMP13MEN1LMNATP53
SCHEMBL1983940 0.80 AR (0.47) ARMMP13MEN1LMNATP53
SCHEMBL1980132 0.78 AR (0.50) OXTRARMMP13MEN1LMNA
SCHEMBL30939608 0.78 AR (0.50) OXTRARMMP13MEN1LMNA
SCHEMBL1979597 0.78 AR (0.47) OXTRARMMP13SLC6A4TP53
SCHEMBL30939562 0.78 AR (0.47) OXTRARMMP13SLC6A4TP53
SCHEMBL30939522 0.77 AR (0.42) ARMMP13NPBWR1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 US disclosed
WO-2013175211-A1 HYDANTOIN DERIVATIVES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-11-28 WO disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 OXTR 890/4885AR 4780/4885MMP13 3121/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 OXTR 890/4885AR 4780/4885MMP13 3121/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 OXTR 890/4885AR 4780/4885MMP13 3121/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 OXTR 890/4885AR 4780/4885MMP13 3121/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 OXTR 890/4885AR 4780/4885MMP13 3121/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 OXTR 1116/4885AR 4434/4885MMP13 1693/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 OXTR 1143/4885AR 4638/4885MMP13 3155/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 OXTR 1116/4885AR 4434/4885MMP13 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.